Relypsa, Inc. (Nasdaq:RLYP), a California-based biopharmaceutical company, announced the pricing of an underwritten public offering of 3,591,836 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately $88 million, as detailed in the press release below issued by the company. Relypsa expects to close its public offering on or about April 16, 2014, subject to satisfaction of customary closing conditions and the company estimates net proceeds from the offering to be approximately $82 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Relypsa has granted the underwriters a 30-day option to purchase up to an additional 538,775 shares of common stock. Latham & Watkins LLP represented Relypsa in the follow on offering, as well as its November 2013 initial public offering, with a corporate team consisting of partners Mark Roeder and Alan Mendelson and associates Brian Cuneo, Saied Pinto and John Williams in the firm’s Silicon Valley office